Ronald Volney
Family Medicine · Middleboro, MANPI 1720296098
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 434 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,582 and has fallen 97.9% since, to $34 in 2025. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$908
- Novo Nordisk$551
- AstraZeneca$535
- GSK$475
- Arbor Pharmaceuticals, Inc.$299
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,971100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,971 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,716 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,409 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 51 | $3,651 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 11 | $3,543 |
| Atorvastatin Calcium | 92 | $1,408 |
| Bumetanide | 16 | $802 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $749 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 13 | $677 |
| Gabapentin | 31 | $637 |
| Omeprazole | 49 | $597 |
| Levothyroxine Sodium | 42 | $517 |
| Pantoprazole Sodium | 17 | $486 |
| Metformin Hcl | 37 | $481 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 22 | $469 |
| Losartan Potassium | 35 | $440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $475 | $16,12429 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $299 | $3,54311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Middleboro
- Raquel VolneyMiddleboro$7K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.